US Pharma MarketingThe post Endeavor’s Phase IIb IPF study of taladegib meets endpoints appeared first on Clinical Trials Arena.
Endeavor’s Phase IIb IPF study of taladegib meets endpoints
Endeavor BioMedicines has reported that its Phase IIb WHISTLE-PF clinical trial assessing taladegib achieved its primary and several key secondary endpoints in IPF patients. The trial evaluated 213 participants with IPF over a 24-week period across 74 medical centres located in 14 countries. Taladegib is an inhibitor targeting the Hedgehog signalling pathway to suppress abnormal cellular scarring in fibrotic pulmonary conditions. Credit: Antonio Marca/Shutterstock.com. Endeavor BioMedicines has reported that its Phase IIb WHISTLE-PF clinical trial assessing taladegib (ENV-101) achieved its primary and several key secondary endpoints in idiopathic pulmonary fibrosis (IPF) patients. The double-blind, randomised, dose-ranging, placebo-controlled, multi-centre trial evaluated…
Endeavor BioMedicines has reported that its Phase IIb WHISTLE-PF clinical trial assessing taladegib achieved its primary and several key secondary endpoints in IPF patients.
Source: Clinical Trials Arena